KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) EBITDA (2016 - 2025)

Novavax has reported EBITDA over the past 16 years, most recently at $14.2 million for Q4 2025.

  • Quarterly results put EBITDA at $14.2 million for Q4 2025, up 110.86% from a year ago — trailing twelve months through Dec 2025 was $452.8 million (up 281.9% YoY), and the annual figure for FY2025 was $452.8 million, up 281.9%.
  • EBITDA for Q4 2025 was $14.2 million at Novavax, up from -$178.0 million in the prior quarter.
  • Over the last five years, EBITDA for NVAX hit a ceiling of $515.5 million in Q1 2025 and a floor of -$825.0 million in Q4 2021.
  • Median EBITDA over the past 5 years was -$139.4 million (2024), compared with a mean of -$134.7 million.
  • Biggest five-year swings in EBITDA: crashed 1931.06% in 2021 and later surged 455.94% in 2025.
  • Novavax's EBITDA stood at -$825.0 million in 2021, then surged by 70.44% to -$243.9 million in 2022, then increased by 24.73% to -$183.6 million in 2023, then rose by 28.59% to -$131.1 million in 2024, then surged by 110.86% to $14.2 million in 2025.
  • The last three reported values for EBITDA were $14.2 million (Q4 2025), -$178.0 million (Q3 2025), and $101.1 million (Q2 2025) per Business Quant data.